Sugi Predict

Sugi Predict / Compounds / SCHEMBL20567196

SCHEMBL20567196

SCHEMBL20567196

C[C@H]1C[C@@H](N(C)Cc2cccc(C(F)(F)F)c2)CCN1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 4/20 0.54
▸ SLC6A4 P31645 4/20 0.54
▸ OPRM1 P35372 1/20 0.44
▸ OPRL1 P41146 1/20 0.44
▸ SLC6A3 Q01959 2/20 0.41
▸ TACR1 P25103 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ DCUN1D1 Q96GG9 1/20 0.41
▸ PSEN1 P49768 1/20 0.41
▸ PSEN2 P49810 1/20 0.41
▸ APH1B Q8WW43 1/20 0.41
▸ NCSTN Q92542 1/20 0.41
▸ APH1A Q96BI3 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HTR2C P28335 2/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24970327 1.00 SLC6A2 (0.54) SLC6A2SLC6A4OPRM1OPRL1SLC6A3
SCHEMBL20920392 0.88 SLC6A4 (0.50) SLC6A2SLC6A4OPRM1OPRL1SLC6A3
SCHEMBL25487549 0.84 SLC6A4 (0.50) SLC6A2SLC6A4SLC6A3TACR1MEN1
SCHEMBL4246775 0.83 SLC6A2 (0.53) SLC6A2SLC6A4OPRM1OPRL1MEN1
SCHEMBL4247783 0.80 HRH3 (0.54) SLC6A2SLC6A4OPRM1OPRL1SLC6A3
SCHEMBL22878459 0.76 SLC6A2 (0.47) SLC6A2SLC6A4OPRM1OPRL1MEN1
SCHEMBL17285891 0.76 ALDH1A1 (0.56) SLC6A2SLC6A4OPRM1OPRL1HTR2C
SCHEMBL21500972 0.75 SLC6A2 (0.46) SLC6A2SLC6A4OPRM1OPRL1MEN1
SCHEMBL17284449 0.75 SLC6A2 (0.46) SLC6A2SLC6A4OPRM1OPRL1MEN1
SCHEMBL20566782 0.75 AGTR2 (0.46) SLC6A2SLC6A4TACR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 — — US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 — — CN disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 — — CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
CN-110678456-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-05-02 — — CN disclosed
EP-3630744-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2023-01-25 — — EP disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 — — US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 — — US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 — — US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 — — US disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 — — EP disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 — — WO disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL SLC6A2 4712/4885SLC6A4 4614/4885OPRM1 841/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL SLC6A2 4712/4885SLC6A4 4614/4885OPRM1 841/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL SLC6A2 4766/4885SLC6A4 4668/4885OPRM1 833/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL SLC6A2 4712/4885SLC6A4 4614/4885OPRM1 841/4885
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL SLC6A2 4712/4885SLC6A4 4614/4885OPRM1 841/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL SLC6A2 4766/4885SLC6A4 4668/4885OPRM1 833/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL SLC6A2 4712/4885SLC6A4 4614/4885OPRM1 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.